Trial Profile
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma - a Nordic Lymphoma Group Trial
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jan 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms LENA-BERIT
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 17 Jun 2018 Results exploring the additive effect of lenalidomide were presented at the 23rd Congress of the European Haematology Association
- 12 Mar 2018 Status changed from active, no longer recruiting to completed.